Compare S&P500 ETF (SPY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? S&P500 ETF trades at $766.27 (market cap $821.11B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: S&P500 ETF is far larger — about 109.2× Spyre Therapeutics Inc. Common Stock's market cap, and S&P500 ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 206 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SPY | SYRE | |
|---|---|---|
Market Cap | $821.11B | $7.52B |
Volume | 25,825,560 | 1,441,031 |
52-Week High | $779.14 | $108.92 |
52-Week Low | $631.99 | $22.18 |
Typical Hold Time | 206 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY (SPDR S&P 500 ETF Trust) trades at $778.05, showing minimal daily movement with a slight decline of -0.02 (-0.0%). Technical indicators signal a bullish trend with strong moving average support, though oscillators remain neutral. The ETF maintains its position as the primary S&P 500 tracking fund with upcoming dividend distribution scheduled for October 2026.
The ETF's outlook remains tied to broader market performance with Wall Street monitoring earnings growth projections. Key risks include potential profit growth slowdown from 35% to 15% in 2027 and elevated market valuations. Current technical strength suggests near-term stability, but macroeconomic factors could drive volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
